Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets
NCT01687920 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25
Last updated 2022-02-07
Summary
This study should estimate the dose proportionality of BAY94-8862 IR tablets.
Conditions
Interventions
- DRUG
-
BAY94-8862 (1.25mg)
- DRUG
-
BAY94-8862 (2.5mg)
- DRUG
-
BAY94-8862 (5mg)
- DRUG
-
BAY94-8862 (7.5mg)
- DRUG
-
BAY94-8862 (10mg)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bayer Study Director · Bayer
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 46 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-09-17
- Primary Completion
- 2012-11-28
- Completion
- 2013-03-21
Countries
- Germany
Study Locations
More Related Trials
-
Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose in Participants With Liver Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
NCT04322253 ·Status: TERMINATED ·Phase: PHASE1
-
Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)
NCT02894385 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic and Safety of GSK573719 and GW642444 Administered Individually and Concurrently, With Verapamilin in Healthy Subjects
NCT01128634 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function
NCT06402721 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Study to Investigate Low-dose Combinations of a Cocktail of Seven Drugs for Simultaneous Phenotyping of Cytochromes
NCT01187862 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.
NCT02151994 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants
NCT04249284 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of BIA 5-453 and Its Metabolites
NCT03090724 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Food on the Pharmacokinetics of BI 1060469 (Formulation Tablet) in Healthy Male Subjects
NCT02225626 ·Status: COMPLETED ·Phase: PHASE1
-
A Comparative Pharmacokinetic Study to Evaluate Different Manufacturing Batches of BAT1706 Injection
NCT05865574 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of The Excretion Balance, Pharmacokinetics and Metabolism of A Single Oral Dose of [14C]-Labeled RO4917523 in Healthy Male Volunteers
NCT01592890 ·Status: COMPLETED ·Phase: PHASE1
-
A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet
NCT03804671 ·Status: COMPLETED ·Phase: PHASE1
-
A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers
NCT01684891 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Investigate Safety, Absorption, Elimination, and Drug Effect of BAY2327949 in Participants With Different Renal Function Status
NCT04004195 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment
NCT01767948 ·Status: COMPLETED ·Phase: PHASE1
-
KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
NCT04166942 ·Status: COMPLETED ·Phase: PHASE1
-
STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT
NCT04604496 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function
NCT02001571 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron
NCT00940121 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers
NCT00099450 ·Status: COMPLETED ·Phase: PHASE1
-
Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453
NCT02845037 ·Status: COMPLETED ·Phase: PHASE1
-
Compare the Pharmacokinetic of K-877 Controlled Release (CR) and Immediate Release (IR) Tablets in Healthy Adults.
NCT03702673 ·Status: COMPLETED ·Phase: PHASE1
-
A Study in Healthy Men to Test How BI 1569912 is Processed in the Body
NCT06520553 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment
NCT04587622 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Compared to K-877-IR
NCT04447820 ·Status: COMPLETED ·Phase: PHASE2